Resistance mechanisms of tumour cells to EGFR inhibitors

Clinical and Translational Oncology

Volumn 11, Issue 5, 2009, Pages 270-275

  Morgillo, Floriana ^a   Cantile, Flavia ^a   Fasano, Morena ^a   Troiani, Teresa ^a   Martinelli, Erika ^a   Ciardiello, Fortunato ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

EGFR; Monoclonal antibody; Resistance; Tyrosine kinase inhibitor

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; K RAS PROTEIN; LAPATINIB; RITUXIMAB; SCATTER FACTOR; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

AMINO ACID SUBSTITUTION; COLORECTAL CANCER; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; GENE DELETION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; POINT MUTATION; REVIEW; SOMATIC MUTATION; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 68849119542     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0354-6     Document Type: Review

References (61)

1. S. Bogdan C. Klambt 2001 Epidermal growth factor receptor signaling Curr Biol 11 292 295 10.1016/S0960-9822(01)00167-1 (Pubitemid 32324746)
2. F.R. Hirsch S. Witta 2005 Biomarkers for prediction of sensitivity to EGFR inhibitors in nonsmall cell lung cancer Curr Opin Oncol 17 118 122 15725915 10.1097/01.cco.0000155059.39733.9d 1:CAS:528:DC%2BD2MXhsFSmtbw%3D (Pubitemid 40516280)
3. A.E. Wakeling S.P. Guy J.R. Woodburn, et al. 2002 ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res 62 5749 5754 12384534 1:CAS:528:DC%2BD38XotFyktr8%3D
4. B. Liu M. Fang Y. Lu, et al. 2001 Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody Oncogene 20 1913 1922 11313939 10.1038/sj.onc.1204277 1:CAS:528:DC%2BD3MXivFKht78%3D (Pubitemid 32458701)
5. A.B. Motoyama N.E. Hynes H.A. Lane 2002 The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res. 62 3151 3158 12036928 1:CAS:528:DC%2BD38XksVyqs70%3D
6. S. Khambata-Ford C.R. Garrett N.J. Meropol, et al. 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol. 25 3230 3237 17664471 10.1200/JCO.2006.10.5437 1:CAS:528:DC%2BD2sXhtVWqs7rF (Pubitemid 47325606)
7. M. Guix A.C. Faber S.E. Wang, et al. 2008 Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGFbinding proteins J Clin Invest 118 2609 2619 18568074 1:CAS:528:DC%2BD1cXot1Onurk%3D
8. C.A. Learn T.L. Hartzell C.J. Wikstrand, et al. 2004 Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme Clin Cancer Res 10 3216 3224 15131063 10.1158/1078-0432.CCR-03-0521 1:CAS:528:DC%2BD2cXjs12lt7Y%3D (Pubitemid 38619703)
9. B. Li M. Yuan I.A. Kim, et al. 2004 Mutant epidermal growth factor receptor displays increased signalling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin Oncogene 23 4594 4602 15077177 10.1038/sj.onc.1207602 1:CAS:528: DC%2BD2cXksV2gsro%3D (Pubitemid 38850407)
10. T.J. Lynch D.W. Bell R. Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
11. J.G. Paez P.A. Janne J.C. Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
12. H. Shigematsu L. Lin T. Takahashi, et al. 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 339 346 15741570 1:CAS:528:DC%2BD2MXitV2jsb4%3D (Pubitemid 40425952)
13. S.W. Han T.Y. Kim P.G. Hwang, et al. 2005 Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2493 2501 15710947 10.1200/JCO.2005.01.388 1:CAS:528:DC%2BD2MXjvVyktL0%3D (Pubitemid 47050839)
14. T. Mitsudomi T. Kosaka H. Endoh, et al. 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 23 2513 2520 15738541 10.1200/JCO.2005.00.992 1:CAS:528: DC%2BD2MXjvVyktLs%3D (Pubitemid 47050841)
15. W. Pao V.A. Miller K.A. Politi, et al. 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoSMed 2 e73
16. M.N. Balak Y. Gong G.J. Riely, et al. 2006 Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin Cancer Res 12 6494 6501 17085664 10.1158/1078-0432.CCR-06-1570 1:CAS:528:DC%2BD28XhtFKitbrI (Pubitemid 44799723)
17. S. Schubbert 2007 Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 295 308 17384584 10.1038/nrc2109 1:CAS:528:DC%2BD2sXjtlyhtLs%3D (Pubitemid 46480970)
18. S. Forbes J. Clements E. Dawson, et al. 2006 Cosmic Br J Cancer 94 318 322 16421597 10.1038/sj.bjc.6602928 1:STN:280:DC%2BD28%2FksFagsg%3D%3D (Pubitemid 43151554)
19. J.L. Bos 1989 ras oncogenes in human cancer: a review Cancer Res 49 4682 4689 2547513 1:CAS:528:DyaL1MXltlWksL4%3D
20. E.R. Fearon B. Vogelstein 1990 A genetic model for colorectal tumorigenesis Cell 61 759 767 2188735 10.1016/0092-8674(90)90186-I 1:CAS:528:DyaK3cXktlyhtrg%3D (Pubitemid 20185636)
21. S. Benvenuti A. Sartore-Bianchi F. Di Nicolantonio, et al. 2007 Oncogenic activation of the RAS/ RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res. 67 2643 2648 17363584 10.1158/0008-5472.CAN-06-4158 1:CAS:528:DC%2BD2sXivV2ns7w%3D (Pubitemid 46548951)
22. E. Van Cutsem I. Lang G. D'haens, et al. 2008 KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience J Clin Oncol 26 [Suppl] 5s
23. W. Pao T.Y. Wang G.J. Riely, et al. 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR Kinase Domain PLoS Med 2 e17 15696205 10.1371/journal.pmed.0020017 (Pubitemid 40412734)
24. D.A. Eberhard B.E. Johnson L.C. Amler, et al. 2005 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 5900 5999 16043828 10.1200/JCO.2005.02.857 1:CAS:528:DC%2BD2MXhtVKgtbzO (Pubitemid 46300206)
25. M.S. Tsao A. Sakurada J.C. Cutz, et al. 2005 Erlotinib in lung cancer: molecular and clinical predictors of outcome N Engl J Med 353 133 144 16014883 10.1056/NEJMoa050736 1:CAS:528:DC%2BD2MXmtFejt70%3D (Pubitemid 41058345)
26. F. Di Nicolantonio M. Martini F. Molinari, et al. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705 5712 19001320 10.1200/JCO.2008.18.0786
27. J.A. Engelman K. Zejnullahu T. Mitsudomi, et al. 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039 1043 17463250 10.1126/science.1141478 1:CAS:528: DC%2BD2sXltlOjt7g%3D (Pubitemid 46799492)
28. J. Bean C. Brennan J.Y. Shih, et al. 2007 MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci USA 104 20932 20937 18093943 10.1073/pnas.0710370104 1:CAS:528:DC%2BD1cXktlyhsg%3D%3D
29. P.C. Ma G. Maulik J. Christensen, et al. 2003 c-Met: structure, functions and potential for therapeutic inhibition Cancer Metastasis Rev 22 309 332 12884908 10.1023/A:1023768811842 1:CAS:528:DC%2BD3sXjslyiurY%3D (Pubitemid 36791889)
30. C. Birchmeier W. Birchmeier E. Gherardi, et al. 2003 Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 915 925 14685170 10.1038/nrm1261 1:CAS:528:DC%2BD3sXpvFeju7s%3D (Pubitemid 37493640)
31. B. Lutterbach Q. Zeng L.J. Davis, et al. 2007 Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival Cancer Res 67 2081 2088 17332337 10.1158/0008-5472.CAN-06-3495 1:CAS:528:DC%2BD2sXitlSjsr4%3D (Pubitemid 46424226)
32. C. Sell M. Rubini R. Rubin, et al. 1993 Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor Proc Natl Acad Sci USA 90 11217 11221 8248231 10.1073/pnas.90.23.11217 1:CAS:528:DyaK2cXnsVCrsg%3D%3D (Pubitemid 23354400)
33. R. O'Connor A. Kauffmann-Zeh Y. Liu, et al. 1997 Identification of domains of the insulinlike growth factor I receptor that are required for protection from apoptosis Mol Cell Biol 17 427 435 8972223
34. R. Baserga 1997 The price of independence Exp Cell Res 236 1 3 9344579 10.1006/excr.1997.3732 1:CAS:528:DyaK2sXms1GjtL4%3D (Pubitemid 27452343)
35. H.E. Jones L. Goddard J.M. Gee, et al. 2004 Insulin-like growth factor-I receptor signalling and acquired resistance o gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr Relat Cancer 11 793 814 15613453 10.1677/erc.1.00799 1:CAS:528:DC%2BD2MXhtVartrs%3D (Pubitemid 40065552)
36. A. Chakravarti J.S. Loeffler N.J. Dyson 2002 Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res 62 200 207 11782378 1:CAS:528:DC%2BD38XntV2hsA%3D%3D
37. F. Morgillo J.K. Woo E.S. Kim, et al. 2006 Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib Cancer Res 15 395 399
38. J.G. Christensen R.E. Schreck E. Chan, et al. 2001 High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo Clin Cancer Res 7 4230 4423 11751524 1:CAS:528:DC%2BD38XltFSgtw%3D%3D
39. D. Karunagaran E. Tzahar R.R. Beerli, et al. 1996 ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer EMBO J 15 254 8617201 1:CAS:528:DyaK28XovFSksQ%3D%3D
40. W. Xia Y.K. Lau H.Z. Zhang, et al. 1999 Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members Clin Cancer Res 5 4164 4174 10632356 1:CAS:528:DC%2BD3cXlsV2gtA%3D%3D
41. M. Tateishi T. Ishida S. Kohdono 1994 Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma Surg Oncol 3 109 113 7952390 10.1016/0960-7404(94)90006-X 1:STN:280:DyaK2M%2FktVWitA%3D%3D (Pubitemid 24237138)
42. X. Qian W.C. Dougall M.E. Hellman 1994 Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation Oncogene 9 1507 1514 7908733 1:CAS:528:DyaK2cXivFSks7o%3D
43. D. Graus-Porta R.R. Beerli N.E. Hynes 1995 Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling Mol Cell Biol 15 1182 1191 7532277 1:CAS:528:DyaK2MXjsl2rsb4%3D
44. G.E. Konecny M.D. Pegram N. Venkatesan, et al. 2006 Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 1630 1639 16452222 10.1158/0008-5472.CAN-05-1182 1:CAS:528:DC%2BD28XpsVemsg%3D%3D (Pubitemid 43259947)
45. F. Ciardiello R. Bianco R. Caputo, et al. 2004 Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to Anti-epidermal growth factor receptor therapy Clin Cancer Res 10 784 793 14760102 10.1158/1078-0432.CCR-1100- 03 1:CAS:528:DC%2BD2cXovVKitw%3D%3D (Pubitemid 38174017)
46. J. Milanini F. Vinals J. Pouyssegur, et al. 1998 p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts J Biol Chem 273 18165 18172 9660776 10.1074/jbc.273.29.18165 1:CAS:528:DyaK1cXkvVChtL4%3D (Pubitemid 28334735)
47. F. Ciardiello R. Bianco V. Damiano, et al. 2000 Antiangiogenic and antitumor activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 3739 3747 10999768 1:CAS:528:DC%2BD3cXntFCitrk%3D (Pubitemid 30694960)
48. R.S. Herbst D.H. Johnson E. Mininberg, et al. 2005 Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/ epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent nonsmall-cell lung cancer J Clin Oncol 23 2544 2555 15753462 10.1200/JCO.2005.02.477 1:CAS:528:DC%2BD2MXjvVyktLY%3D
49. J.D. Hainsworth J.A. Sosman D.R. Spigel, et al. 2005 Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib J Clin Oncol 23 7889 7896 16204015 10.1200/JCO.2005.01.8234 1:CAS:528: DC%2BD2MXht1Cqs7fO (Pubitemid 46657387)
50. R.B. Natale D. Bodkin R. Govindan, et al. 2006 ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial Proc Am Soc Clin Oncol 18S 7000
51. J.V. Heymach B.E. Johnson D. Prager, et al. 2006 A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results Proc Am Soc Clin Oncol 18S 7016
52. R. Bianco R. Caputo R. Caputo, et al. 2008 Vascular endothelial growth factor receptor-1 contributes to resistance to anti epidermal growth factor receptor drugs in human cancer cells Clin Cancer Res 4 5069 5080 10.1158/1078-0432.CCR-07-4905
53. M.L. Janmaat F.A. Kruyt J.A. Rodriguez, et al. 2003 Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin Cancer Res 9 2316 2326 12796401 1:CAS:528:DC%2BD3sXksVajs78%3D
54. N. Magne J.L. Fischel A. Dubreuil, et al. 2006 Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa") Br J Cancer 86 1518 1523 10.1038/sj.bjc.6600299
55. R. Bianco I. Shin C.A. Ritter, et al. 2003 Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 22 2812 2822 12743604 10.1038/sj.onc.1206388 1:CAS:528:DC%2BD3sXjsFymt78%3D (Pubitemid 36609595)
56. R.C. Stein 2001 Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment Endocr Relat Cancer 8 237 248 11566615 10.1677/erc.0.0080237 1:CAS:528:DC%2BD3MXotlCqsb8%3D (Pubitemid 32947646)
57. R. Humar F.N. Kiefer H. Berns, et al. 2002 Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling FASEB J 16 771 780 12039858 10.1096/fj.01-0658com 1:CAS:528: DC%2BD38XksVWmsLc%3D (Pubitemid 34615125)
58. M. S. Neshat I.K. Mellinghoff C. Tran, et al. 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci U S A 98 10314 10319 11504908 10.1073/pnas.171076798 1:CAS:528:DC%2BD3MXmvFWiurk%3D (Pubitemid 32803017)
59. M. Guba P. von Breitenbuch M. Steinbauer, et al. 2002 Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 128 135 11821896 10.1038/nm0202-128 1:CAS:528:DC%2BD38Xht1equrY%3D (Pubitemid 34155123)
60. R.D. Rao A.C. Mladek J.D. Lamont, et al. 2005 Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells Neoplasia 7 921 929 16242075 10.1593/neo.05361 1:CAS:528:DC%2BD2MXhtlClurvP
61. S. Di Cosimo P. Matar F. Rojo, et al. 2004 Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001) Proc Am Soc Clin Oncol 14S 3074